Telix to Host Expert Forum on PSMA-targeting Radiopharmaceuticals including ProstACT Therapy Program of First-in-Class rADC, TLX591

Melbourne (Australia) | 16 November 2023

Telix today advises it will host an investor webcast on Tuesday, 21 November 2023, from 10.15am AEDT (12:15am CET / 6.15pm EST, 20 November).

Telix Group Chief Medical Officer, Dr Colin Hayward, will moderate an expert discussion with global key opinion leaders listed below on the evolving treatment landscape for PSMA-targeted radiopharmaceuticals, including Telix’s first-in-class investigational radio-antibody drug conjugate (rADC), TLX591 (¹⁷⁷Lu-rosopatamab tetraxetan).

Topics will include ProstACT GLOBAL study design (ClinicalTrials.gov ID: NCT04876651), and recent data from Telix’s ProstACT SELECT study (ClinicalTrials.gov ID: NCT04786847) which reinforces the potential benefits of the antibody-based approach.

Participants can register for the webcast at the following link: https://ccmediaframe.com/?id=9PnyQ7Vh

A recording of the webcast will also be made available on the Company’s website.

Key Opinion Leaders

Scott T. Tagawa

Scott T. Tagawa, MD, is a New York-based Professor of Medicine and Urology. Dr Tagawa’s research focuses on clinical and translational investigations in genitourinary tumours and thrombosis in malignancy. Additionally, he specialises in drug development and theranostics in prostate cancer. He was co-PI of the VISION trial (ClinicalTrials.gov ID: NCT03511664), an international Phase III study of ¹⁷⁷Lu-PSMA in advanced prostate cancer and is a Fellow of the American Society of Clinical Oncology (ASCO).

Oliver Sartor

Oliver Sartor, MD, is an internationally recognised expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 400 peer-reviewed articles, led or co-led multiple national and international clinical studies, including three Phase III studies pivotal for FDA approval. He was also co-PI of the VISION trial.

Nat Lenzo

Nat Lenzo, MD, is an adjunct clinical professor in Medicine at Curtin University and Notre Dame University Australia. He also works as a consultant nuclear physician and acute medicine physician at Fiona Stanley Hospital, and general physician at St John of God Hospital Murdoch. With a track record in developing clinical and research services in both the public and private sectors, Dr Lenzo has an interest in oncology and theranostics. He is the co-investigator on a number of grants, a principal investigator in several clinical trials, and a co-author on many peer-reviewed publications.